Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Tevimbra Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0262

    Tevimbra (tislelizumab-jsgr) Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0262 alerts

    Get alerted when Policy CC-0262 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This medical drug clinical policy governs prior authorization and medical necessity review for intravenous Tevimbra (tislelizumab-jsgr) in adults and other individuals with specified cancers. Coverage is available only for listed FDA-approved or NCCN-compendial indications when the stated disease, biomarker, treatment-line, combination-therapy, and prior-treatment criteria are met.

    Policy Summary
    PayerEmpire Bluecross
    PolicyTevimbra (tislelizumab-jsgr) Coverage and Prior Authorization
    Policy CodePolicy CC-0262
    Change TypeModified
    Effective DateOct 27, 2026
    Last ReviewSep 14, 2026
    Next Review DateN/A
    Key ActionSubmit Tevimbra requests for prior authorization under the medical benefit and document the diagnosis, treatment line, required biomarkers, prior therapy, ECOG status when applicable, and planned combination regimen.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added the FDA indication for Tevimbra in combination with Ziihera and fluoropyrimidine- and platinum-containing chemotherapy for HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.

    The policy added NCCN 2A criteria for Tevimbra with paclitaxel and carboplatin in anal carcinoma.

    The policy added NCCN 2A recommendations for classic Hodgkin lymphoma and endometrial carcinoma.

    The policy added NCCN criteria for appendiceal cancer and separated small bowel adenocarcinoma criteria from colorectal cancer criteria.

    The policy removed HER2 requirements from the esophageal squamous cell carcinoma criteria and removed ECOG requirements from the gastric and gastroesophageal junction criteria.

    The policy clarified CLL/SLL eligibility for del(17p)/TP53-mutated disease or disease that is chemotherapy refractory or unable to receive chemoimmunotherapy.

    The policy added an FDA indication for Tevimbra in combination with Ziihera for gastric, gastroesophageal junction, and esophageal adenocarcinoma.

    The policy added NCCN category 2A criteria for Tevimbra in combination with paclitaxel and carboplatin for anal carcinoma, classic Hodgkin lymphoma, and endometrial carcinoma.

    The policy revised criteria for esophageal squamous cell carcinoma, gastric and gastroesophageal junction cancers, chronic lymphocytic leukemia/small lymphocytic lymphoma, anal carcinoma, colorectal cancer, nasopharyngeal cancer, and hepatocellular carcinoma.

    The policy added NCCN recommendations for appendiceal cancer, small bowel adenocarcinoma, nasopharyngeal cancer, hepatocellular carcinoma, and other specified malignancies.

    The policy replaced HCPCS J3590 and J9999 with HCPCS J9329 and added or revised multiple ICD-10-CM codes during coding reviews.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    14Clinical criteria pathways
    J9329Current billing code
    13NCCN compendial cancer-use categories
    ≥1PD-L1 threshold
    0-2Performance-status range
    FDA indicationNew combination use

    Covered Indications and Approval Rules

    Covered indications and treatment pathways

    Requests may be approved if at least one of the following clinical pathways is met.

    Approved clinical pathways

    • I. Pediatric request

      • Individual is under 19 years of age.Age <19 years
    • II. Esophageal squamous cell carcinoma

      • Individual has unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).
      • ONE of

        • Disease has progressed after prior systemic chemotherapy that did not include a PD-L1 inhibitor as a single agent.
        • Tevimbra is used as first-line therapy in combination with platinum-containing chemotherapy for a tumor expressing PD-L1.PD-L1 >=1
    • III. HER2-negative gastric, GEJ, or esophageal cancer

      • Individual has unresectable locally advanced, recurrent, or metastatic esophageal or esophagogastric junction cancer, or gastric cancer.
      • Disease is unresectable or metastatic and HER2-negative.
      • Tumor expresses PD-L1.PD-L1 >=1
      • Tevimbra is used as first-line therapy.
      • Individual has not received another anti-PD-1 or anti-PD-L1 agent, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
      • Tevimbra is used in combination with platinum and fluoropyrimidine-based chemotherapy.
    • IV. Induction therapy for dysphagia

      • Individual has esophageal or esophagogastric junction cancer.
      • Tevimbra is used as induction systemic therapy to relieve dysphagia.
      • Tumor has a PD-L1 combined positive score.CPS >=1
      • Tevimbra is used in combination with platinum and fluoropyrimidine-based chemotherapy.
    • V. HER2-positive gastric, GEJ, or esophageal adenocarcinoma

      • Individual has gastric, gastroesophageal junction, or esophageal adenocarcinoma.
      • Disease is HER2-positive unresectable locally advanced or metastatic disease.HER2-positive: IHC 3+ or IHC 2+/ISH+
      • Tevimbra is used as first-line treatment in combination with Ziihera (zanidatamab-hrii) and fluoropyrimidine- and platinum-containing chemotherapy.
    • VI. CLL/SLL with Richter transformation

      • Individual has chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).
      • Tevimbra is used in combination with Brukinsa (zanubrutinib) for histologic (Richter) transformation to diffuse large B-cell lymphoma.
      • ONE of

        • Individual has a del(17p)/TP53 mutation.
        • Individual is chemotherapy refractory or unable to receive chemoimmunotherapy.
    • VII. Metastatic anal carcinoma

      • Individual has metastatic anal carcinoma.
    • VIII. Appendiceal carcinoma

      • Individual has appendiceal carcinoma with advanced or metastatic disease.
      • ONE of

        • Disease is deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H).
        • Disease has POLE/POLD1 with an ultra-hypermutated phenotype.TMB >50 mut/Mb
      • ONE of

        • Tevimbra is used as second-line or subsequent therapy, as a single agent, and the individual has not received a prior anti-PD-1 or anti-PD-L1 agent.
        • Tevimbra is used in combination with paclitaxel and carboplatin.
    • IX. Colorectal cancer

      • Individual has colorectal cancer.
      • ONE of

        • Disease is dMMR/MSI-H.
        • Disease has POLE/POLD1 with an ultra-hypermutated phenotype.TMB >50 mut/Mb
    • X. Small bowel adenocarcinoma

      • Individual has small bowel adenocarcinoma.
      • ONE of

        • Disease is dMMR/MSI-H.
        • Disease has POLE/POLD1 with an ultra-hypermutated phenotype.TMB >50 mut/Mb
    • XI. Metastatic nasopharyngeal cancer

      • Individual has metastatic nasopharyngeal cancer that is squamous cell carcinoma.
      • Tevimbra is used as systemic therapy in combination with cisplatin and gemcitabine for subsequent-line therapy.
      • Current ECOG performance status is 0-2.ECOG 0-2
    • XII. Classic Hodgkin lymphoma

      • Individual has classic Hodgkin lymphoma.
      • Tevimbra is used in combination with gemcitabine and oxaliplatin.
    • XIII. Hepatocellular carcinoma

      • Individual has hepatocellular carcinoma.
      • Tevimbra is used as a single agent.
    • XIV. Endometrial or uterine carcinoma

      • Individual has endometrial or uterine carcinoma.
      • Tevimbra is used as second-line or subsequent therapy.
      • Tevimbra is used as a single agent.
      • The tumor is recurrent and MSI-H or dMMR.Recurrent MSI-H or dMMR

    All indications not listed in the approval criteria are not approved. Coverage is limited to the specified FDA-approved or NCCN-compendial pathways.

    Requests for Tevimbra (tislelizumab-jsgr) that do not meet the stated clinical criteria may not be approved.

    Initial Therapy Eligibility

    Initial therapy eligibility

    Initial approval may be granted when all requirements of at least one covered clinical pathway are met.

    Initial approval pathways

    • I. Pediatric request

      • Individual is under 19 years of age.Age <19 years
    • II. Esophageal squamous cell carcinoma

      • Individual has unresectable locally advanced, recurrent, or metastatic ESCC.
      • ONE of

    Billing and Diagnosis Coding

    HCPCSHCPCS
    J9329Injection, tislelizumab-jsgr, 1mg [Tevimbra]
    ICD-10 DiagnosisICD-10
    C11.0-C11.9Malignant neoplasm of nasopharynx
    C14.0Malignant neoplasm of pharynx, unspecified
    C14.2Malignant neoplasm of Waldeyer's ring
    C15.3-C15.9Malignant neoplasm of esophagus
    C16.0-C16.9Malignant neoplasm of stomach
    C17.0-C17.9Malignant neoplasm of small intestine
    C18.0-C18.9Malignant neoplasm of colon
    C19Malignant neoplasm of rectosigmoid junction
    C20Malignant neoplasm of rectum
    C21.0-C21.8Malignant neoplasm of anus and anal canal
    1–10 of 24
    1/3
    ICD-10-CM codes added in 2026 coding reviewsICD-10
    C31.0ICD-10-CM code added during the 09/14/2026 coding review
    C31.1ICD-10-CM code added during the 09/14/2026 coding review
    C14.0ICD-10-CM code added during the 05/15/2026 coding review
    C14.2ICD-10-CM code added during the 05/15/2026 coding review
    C54.0-C54.9ICD-10-CM range added during the 05/15/2026 coding review
    C55ICD-10-CM code added during the 05/15/2026 coding review
    C81.10-C81.99ICD-10-CM range added during the 05/15/2026 coding review
    ICD-10-CM codes added or revised in 2025 coding reviewsICD-10
    C11.0-C11.9ICD-10-CM range added during the 05/16/2025 coding review
    C17.0-C21.8ICD-10-CM range added during the 05/16/2025 coding review
    C22.0ICD-10-CM code added during the 05/16/2025 coding review
    C22.8ICD-10-CM code added during the 05/16/2025 coding review
    C22.9ICD-10-CM code added during the 05/16/2025 coding review
    C30.0ICD-10-CM code added during the 05/16/2025 coding review
    C15.3-C15.9Consolidated ICD-10-CM range referenced in the 02/21/2025 coding review
    C16.0-C16.9ICD-10-CM range added during the 02/21/2025 coding review
    C83.00-C83.09ICD-10-CM range added during the 02/21/2025 coding review
    C83.30-C83.38ICD-10-CM range added during the 02/21/2025 coding review
    1–10 of 12
    1/2
    HCPCS codesHCPCS
    J3590HCPCS code previously added for Tevimbra and later removed
    J9999HCPCS code previously added for Tevimbra and later removed
    J9329HCPCS code replacing J3590 and J9999
    Additional ICD-10-CM codesICD-10
    C15.3ICD-10-CM code added in the original coding review
    C15.4ICD-10-CM code added in the original coding review
    C15.5ICD-10-CM code added in the original coding review
    C15.8ICD-10-CM code added in the original coding review
    C15.9ICD-10-CM code added in the original coding review
    Z85.01ICD-10-CM code added in the original coding review
    PD-L1 tumor expression
    Required PD-L1 expressionPD-L1 ≥1
    First-line ESCC useRequired for first-line Tevimbra in combination with platinum-containing chemotherapy for tumors with PD-L1 ≥1.
    Gastric, GEJ, or esophageal cancer useRequired for first-line therapy of unresectable or metastatic HER2-negative disease in combination with platinum and fluoropyrimidine-based chemotherapy.
    PD-L1 combined positive score
    Required combined positive scorePD-L1 CPS ≥1

    Prior Authorization and Documentation

    Prior Authorization

    Obtain prior authorization before treatment

    Tevimbra requests are subject to clinical review, including prior authorization, under the medical benefit. Approval requires satisfaction of at least one listed clinical criteria pathway.

    Documentation Required

    Submit complete clinical and treatment documentation

    Document the diagnosis and disease extent, treatment line, required biomarker or molecular results, prior systemic or checkpoint-inhibitor therapy, ECOG performance status when applicable, and the planned Tevimbra combination regimen.

    • Include applicable PD-L1 expression or CPS, HER2 status, dMMR/MSI-H or POLE/POLD1 findings, and ultra-hypermutated phenotype results.
    • Document prior anti-PD-1 or anti-PD-L1 therapy and other relevant systemic treatment history.
    • Provide current ECOG performance status when required and identify the planned chemotherapy or combination regimen.

    About Tevimbra

    Tevimbra (tislelizumab-jsgr) is an intravenous programmed death receptor-1 (PD-1) blocking antibody, or immune checkpoint inhibitor, used in selected solid tumors and hematologic malignancies. The policy includes FDA-approved and NCCN-compendial uses across esophageal, gastric and gastroesophageal junction, colorectal, appendiceal, small bowel, anal, nasopharyngeal, hepatocellular, uterine, Hodgkin lymphoma, and CLL/SLL-related disease settings. Eligibility may depend on disease extent, treatment line, biomarker or molecular findings, prior checkpoint-inhibitor exposure, and the planned combination regimen.

    Clinical Definitions

    ECOG or Eastern Cooperative Oncology Group Performance Status
    PurposeA scale and set of criteria used to assess disease progression, effects on daily living, treatment suitability, and prognosis.
    Score rangeScores range from 0 through 5.
    Scale endpoints0 means fully active without restriction; 5 means dead.
    Metastasis
    DefinitionThe spread of cancer from one part of the body to another.
    Metastatic tumor cellsA metastatic tumor contains cells that are like those in the original primary tumor.
    Primary site relationship
    Policy Summary
    PayerEmpire Bluecross
    PolicyTevimbra (tislelizumab-jsgr) Coverage and Prior Authorization
    Policy CodePolicy CC-0262
    Change TypeModified
    Effective DateOct 27, 2026
    Last ReviewSep 14, 2026
    Next Review DateN/A
    Key ActionSubmit Tevimbra requests for prior authorization under the medical benefit and document the diagnosis, treatment line, required biomarkers, prior therapy, ECOG status when applicable, and planned combination regimen.
    SourceLink
    On This Page
    Covered Indications and Approval RulesInitial Therapy EligibilityBilling and Diagnosis CodingPrior Authorization and DocumentationAbout TevimbraClinical Definitions
    Disease has progressed after prior systemic chemotherapy that did not include a PD-L1 inhibitor as a single agent.
  1. Tevimbra is used first-line with platinum-containing chemotherapy for a tumor expressing PD-L1.PD-L1 >=1
  2. III. HER2-negative gastric, GEJ, or esophageal cancer

    • Individual has unresectable locally advanced, recurrent, or metastatic esophageal or esophagogastric junction cancer, or gastric cancer.
    • Disease is unresectable or metastatic and HER2-negative.
    • Tumor expresses PD-L1.PD-L1 >=1
    • Use is first-line.
    • No prior anti-PD-1, anti-PD-L1, or other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
    • Tevimbra is combined with platinum and fluoropyrimidine-based chemotherapy.
  3. IV. Induction therapy for dysphagia

    • Individual has esophageal or esophagogastric junction cancer.
    • Tevimbra is used for induction systemic therapy to relieve dysphagia.
    • PD-L1 combined positive score is at least 1.CPS >=1
    • Tevimbra is combined with platinum and fluoropyrimidine-based chemotherapy.
  4. V. HER2-positive gastric, GEJ, or esophageal adenocarcinoma

    • Individual has gastric, gastroesophageal junction, or esophageal adenocarcinoma.
    • Disease is HER2-positive, unresectable locally advanced or metastatic disease.HER2-positive: IHC 3+ or IHC 2+/ISH+
    • First-line Tevimbra is combined with Ziihera (zanidatamab-hrii) and fluoropyrimidine- and platinum-containing chemotherapy.
  5. VI. CLL/SLL with Richter transformation

    • Individual has CLL/SLL.
    • Tevimbra is combined with Brukinsa (zanubrutinib) for histologic Richter transformation to diffuse large B-cell lymphoma.
    • ONE of

      • del(17p)/TP53 mutation.
      • Chemotherapy-refractory disease or inability to receive chemoimmunotherapy.
  6. VII. Metastatic anal carcinoma

    • Individual has metastatic anal carcinoma.
  7. VIII. Appendiceal carcinoma

    • Individual has advanced or metastatic appendiceal carcinoma.
    • ONE of

      • dMMR/MSI-H disease.
      • POLE/POLD1 with an ultra-hypermutated phenotype.TMB >50 mut/Mb
    • ONE of

      • Second-line or subsequent single-agent Tevimbra, with no prior anti-PD-1 or anti-PD-L1 agent.
      • Tevimbra combined with paclitaxel and carboplatin.
  8. IX. Colorectal cancer

    • Individual has colorectal cancer.
    • ONE of

      • dMMR/MSI-H disease.
      • POLE/POLD1 with an ultra-hypermutated phenotype.TMB >50 mut/Mb
  9. X. Small bowel adenocarcinoma

    • Individual has small bowel adenocarcinoma.
    • ONE of

      • dMMR/MSI-H disease.
      • POLE/POLD1 with an ultra-hypermutated phenotype.TMB >50 mut/Mb
  10. XI. Metastatic nasopharyngeal cancer

    • Individual has metastatic squamous cell carcinoma of the nasopharynx.
    • Tevimbra is used with cisplatin and gemcitabine as subsequent-line systemic therapy.
    • Current ECOG performance status is 0-2.ECOG 0-2
  11. XII. Classic Hodgkin lymphoma

    • Individual has classic Hodgkin lymphoma.
    • Tevimbra is combined with gemcitabine and oxaliplatin.
  12. XIII. Hepatocellular carcinoma

    • Individual has hepatocellular carcinoma.
    • Tevimbra is used as a single agent.
  13. XIV. Endometrial or uterine carcinoma

    • Individual has endometrial or uterine carcinoma.
    • Tevimbra is used as second-line or subsequent single-agent therapy.
    • Tumor is recurrent MSI-H or dMMR.Recurrent MSI-H or dMMR
  14. Clinical setting
    Esophageal or esophagogastric junction cancer receiving induction systemic therapy to relieve dysphagia.
    Required combinationTevimbra must be used in combination with platinum and fluoropyrimidine-based chemotherapy.
    Ultra-hypermutated phenotype
    Associated molecular findingPOLE/POLD1 with an ultra-hypermutated phenotype.
    Tumor mutational burden thresholdTMB >50 mut/Mb
    Covered disease settingsSpecified appendiceal, colorectal, and small bowel adenocarcinoma pathways.
    ECOG performance status
    Required ECOG range0-2
    Assessment timingCurrent ECOG performance status.
    Applicable pathwayMetastatic squamous cell nasopharyngeal cancer treated with subsequent-line systemic therapy in combination with cisplatin and gemcitabine.
    Denial Risk

    Unlisted indications or unmet criteria risk denial

    Requests may not be approved when the listed criteria are not met or for all other indications. Confirm that the requested use corresponds to one of the covered clinical pathways before submitting the request.

    • Unlisted indications are not approved.
    • Tevimbra requests that do not meet the stated clinical criteria may not be approved.
    Denial Risk

    Align the request with an approved clinical pathway

    Ensure the requested disease, treatment line, biomarker, prior therapy, and combination regimen match an approved pathway. A mismatch—such as an incorrect PD-L1 or HER2 status, unsupported MSI/dMMR or POLE/POLD1 finding, prior checkpoint-inhibitor exposure where it is excluded, or an unapproved chemotherapy combination—may prevent approval.

    • Verify the disease and extent, such as unresectable, locally advanced, recurrent, metastatic, or histologic Richter transformation, as applicable.
    • Match the required treatment line and regimen, including specified single-agent, platinum/fluoropyrimidine, Ziihera, Brukinsa, paclitaxel/carboplatin, cisplatin/gemcitabine, or gemcitabine/oxaliplatin combinations.
    • Confirm pathway-specific biomarkers and prior-treatment requirements before requesting authorization.
    Cancer cells spread from the original primary tumor to another part of the body.